Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Rebastinib and paclitaxel for advanced/metastatic ovarian cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses results from the Phase Ib/II trial (NCT03601897) investigating rebastinib and paclitaxel for advanced or metastatic ovarian cancer. Oral rebastinib was combined with standard-of-care paclitaxel chemotherapy, with patients receiving either 50mg BID or 100mg BID of rebastinib. Promising progression-free survival was seen and the most common side effects were due to chemotherapy, which was manageable at a dose of 50mg BID. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Disclosures

Dr. Hamilton discloses research funding (payable to institution only, no personal funds) from: OncoMed, Genentech/Roche, Zymeworks, Rgenix, ArQule, Clovis, Silverback Therapeutics, Millenium, Acerta Pharma, Sermonix Pharmaceuticals, Torque, Black Diamond, Karyopharm, Infinity Pharmaceuticals, Curis, Syndax, Novartis, Boehringer Ingelheim, Immunomedics, FujiFilm, Taiho, Deciphera, Fochon, Molecular Templates, Onconova Therapeutics, Dana Farber Cancer Hospital, Hutchinson MediPharma, MedImmune, SeaGen, Puma Biotechnology, Compugen, TapImmune, Lilly, Pfizer, H3 Biomedicine, Takeda, Merus, Regeneron, Arvinas, StemCentRx, Verastem, eFFECTOR Therapeutics, CytomX, InventisBio, Lycera, Mersana, Radius Health, Abbvie, Nucana, Leap Therapeutics, Zenith Epigenetics, Harpoon, Orinove, AstraZeneca, Tesaro, Macrogenics, EMD Serono, Daiichi Sankyo, Syros, Sutro, G1 Therapeutics, Merck, PharmaMar, Olema, Polyphor, Immunogen, Plexxicon, Amgen, Akesobio Australia, Shattuck Labs.

D. Hamilton discloses consulting/advisory role payments (to institution only, no personal funds accepted) from: Genentech/Roche, Boehringer Ingelheim, Novartis, Dantari, Lilly, Merck, Puma Biotechnology, Silverback Therapeutics, CytomX, Pfizer, Mersana, Black Diamond, H3 Biomedicine, Daiichi Sankyo, AstraZeneca, Arvinas, Deciphera Pharmaceuticals, Eisai, Seagen.